General practitioner practice-based pharmacist input to medicines optimisation in the UK: pragmatic, multicenter, randomised, controlled trial

Nadia Farhanah Syafhan, Sayer Al Azzam, Steven D Williams, Wendy Wilson, Jayne Brady, Peter Lawrence, Mark McCrudden, Mustafa Ahmed, Michael G Scott, Glenda Fleming, Anita Hogg, Claire Scullin, Robert Horne, Harblas Ahir, James C McElnay, Nadia Farhanah Syafhan, Sayer Al Azzam, Steven D Williams, Wendy Wilson, Jayne Brady, Peter Lawrence, Mark McCrudden, Mustafa Ahmed, Michael G Scott, Glenda Fleming, Anita Hogg, Claire Scullin, Robert Horne, Harblas Ahir, James C McElnay

Abstract

Background: Changing demographics across the UK has led to general practitioners (GPs) managing increasing numbers of older patients with multi-morbidity and resultant polypharmacy. Through government led initiatives within the National Health Service, an increasing number of GP practices employ pharmacist support. The purpose of this study is to evaluate the impact of a medicines optimisation intervention, delivered by GP practice-based pharmacists, to patients at risk of medication-related problems (MRPs), on patient outcomes and healthcare costs.

Methods: A multi-centre, randomised (normal care or pharmacist supplemented care) study in four regions of the UK, involving patients (n = 356) from eight GP practices, with a 6-month follow-up period. Participants were adult patients who were at risk of MRPs.

Results: Median number of MRPs per intervention patient were reduced at the third assessment, i.e. 3 to 0.5 (p < 0.001) in patients who received the full intervention schedule. Medication Appropriateness Index (MAI) scores were reduced (medications more appropriate) for the intervention group, but not for control group patients (8 [4-13] to 5 [0-11] vs 8 [3-13] to 7 [3-12], respectively; p = 0.001). Using the intention-to-treat (ITT) approach, the number of telephone consultations in intervention group patients was reduced and different from the control group (1 [0-3] to 1 [0-2] vs 1 [0-2] to 1 [0-3], p = 0.020). No significant differences between groups were, however, found in unplanned hospital admissions, length of hospital stay, number of A&E attendances or outpatient visits. The mean overall healthcare cost per intervention patient fell from £1041.7 ± 1446.7 to £859.1 ± 1235.2 (p = 0.032). Cost utility analysis showed an incremental cost per patient of - £229.0 (95% CI - 594.6, 128.2) and a mean QALY gained of 0.024 (95% CI - 0.021 to 0.065), i.e. indicative of a health status gain at a reduced cost (2016/2017).

Conclusion: The pharmacist service was effective in reducing MRPs, inappropriateness of medications and telephone consultations in general practice in a cost-effective manner.

Trial registration: ClinicalTrials.Gov, NCT03241498. Registered 7 August 2017-Retrospectively registered, https://ichgcp.net/clinical-trials-registry/NCT03241498.

Keywords: Clinical pharmacist; General practice; Healthcare resource utilisation; Medicines optimisation; Practice-based pharmacist.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Study flowchart
Fig. 2
Fig. 2
Flowchart of patient flows from invited to participate to completion of end of study questionnaires
Fig. 3
Fig. 3
Sub-categories of medication-related problems identified at baseline and third assessment in patients (n = 118) who received three pharmacist interventions
Fig. 4
Fig. 4
Frequency of inappropriate MAI criteria (n = 63 intervention patients; intention-to-treat group)

References

    1. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross sectional study’. Lancet. 2012;380:37–43. doi: 10.1016/S0140-6736(12)60240-2.
    1. Office for National Statistics. National Population Projections: 2014-based Statistical Bulletin. 2015. . Accessed 25 Oct 2016.
    1. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: Updating the cost-of-illness model. J Am Pharm Assoc. 2001;41:192–199.
    1. American Society of Health-System Pharmacists ASHP statement on pharmaceutical care. AmJ Health Syst Pharm. 1993;50:1720–1723. doi: 10.1093/ajhp/50.8.1720.
    1. Einarson TR. Drug-related hospital admissions. Ann Pharmacother. 1993;27:832–840. doi: 10.1177/106002809302700702.
    1. Zed PJ. Drug-related visits to the emergency department. J Pharm Pract. 2005;18:329–335. doi: 10.1177/0897190005280049.
    1. Nivya K, Kiran VSS, Ragoo N, Jayaprakash B, Sekhar MS. Systemic review on drug related hospital admissions—a pubmed based search. Saudi Pharm J. 2015;23:1–8. doi: 10.1016/j.jsps.2013.05.006.
    1. Elliott R, Camacho E, Campbell F, Jankovic D, Martyn St James M, Kaltenthaler E, Wong R, Sculpher M, Faria R. Prevalence and Economic Burden of Medication Errors in The NHS in England. Rapid evidence synthesis and economic analysis of the prevalence and burden of medication error in the UK. Policy Research Unit in Economic Evaluation of Health and Care Interventions. Universities of Sheffield and York. 2018. . Accessed 5 Dec 2018.
    1. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18.820 patients. BMJ. 2004;329:15–19. doi: 10.1136/bmj.329.7456.15.
    1. Leendertse A, Van Den Bemt PM, Poolman JB, Stoker LJ, Egberts AC, Postma MJ. Preventable hospital admissions related to medication (HARM): cost analysis of the HARM study. Value Health. 2011;14:34–40. doi: 10.1016/j.jval.2010.10.024.
    1. National Health Service (NHS) England. Pharmaceutical waste reduction in NHS. 2015. . Accessed 25 May 2016.
    1. Al-Eidan FA, McElnay JC, Scott MG, McConnell JB. Management of Helicobacter pylori eradication-the influence of structured counselling and follow-up. Br J Clin Pharmacol. 2002;53:163–171. doi: 10.1046/j.0306-5251.2001.01531.x.
    1. Richardson TE, O’reilly CL, Chen TF. Drug-related problems and the clinical role of pharmacists in inpatient mental health: an insight into practice in Australia. Int J Clin Pharm. 2014;36:1077–1086. doi: 10.1007/s11096-014-9997-7.
    1. Silva C, Ramalho C, Luz I, Monteiro J, Fresco P. Drug-related problems in institutionalized, polymedicated elderly patients: opportunities for pharmacist intervention. Int J Clin Pharm. 2015;37:327–334. doi: 10.1007/s11096-014-0063-2.
    1. Odeh M, Scullin C, Fleming G, Scott MG, Horne R, McElnay JC. Ensuring continuity of patient care across the healthcare interface: telephone follow-up post hospitalization. Br J Clin Pharmacol. 2019;85:616–625. doi: 10.1111/bcp.13839.
    1. National Institute for Health and Care Excellence. Medicines optimisation: the safe and effective use of medicine to enable the best possible outcomes. 2015. . Accessed 26 May 2016.
    1. Sackett D, Rosenberg WMC, Gray JAM, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312:71–72. doi: 10.1136/bmj.312.7023.71.
    1. Elwyn G, Laitner S, Coulter A, Walker E, Watson P, Thomson R. Implementing shared decision making in the NHS. BMJ. 2010;341:c5146. doi: 10.1136/bmj.c5146.
    1. Greenhalgh T, Howick J, Maskrey N. Evidence based medicine: a movement in crisis? BMJ. 2014;348:g3725. doi: 10.1136/bmj.g3725.
    1. Royal Pharmaceutical Society. Medicine optimisation: Helping patient to make the most of medicine. 2013. . Accessed 26 May 2016.
    1. Hirsch JD, Steers N, Adler DS, Kuo GM, Morello CM, Lang M, Singh RF, Wood Y, Kaplan RM, Mangione CM. Primary care-based, pharmacist–physician collaborative medication-therapy management of hypertension: a randomized, pragmatic trial. Clin Ther. 2014;36:1244–1254. doi: 10.1016/j.clinthera.2014.06.030.
    1. Jorgenson D, Laubscher T, Lyons B, Palmer R. Integrating pharmacists into primary care teams: barriers and facilitators. Int J Pharm Pract. 2014;22:292–299. doi: 10.1111/ijpp.12080.
    1. Simpson SH, Lier DA, Majumdar SR, Tsuyuki RT, Lewanczuk RZ, Spooner R, Johnson JA. Cost-effectiveness analysis of adding pharmacists to primary care teams to reduce cardiovascular risk in patients with Type 2 diabetes: results from a randomized controlled trial. Diabet Med. 2015;32:899–906. doi: 10.1111/dme.12692.
    1. Tan ECK, Stewart K, Elliott RA, George J. Pharmacist consultations in general practice clinics: the pharmacists in practice study (PIPS) Res Soc Adm Pharm. 2014;10:623–632. doi: 10.1016/j.sapharm.2013.08.005.
    1. Hazen ACM, deBont AA, Boelman L, Zwart DLM, deGier JJ, deWit N, Bouby ML. The degree of integration of non-dispensing pharmacists in primary care practice and the impact on health outcomes: a systematic review. Res Soc Adm Pharm. 2018;14:228–240. doi: 10.1016/j.sapharm.2017.04.014.
    1. Beney J, Bero L, Bond CM. Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes. Cochrane Database Syst Rev. 2000;CD000336.
    1. Fish A, Watson MC, Bond CM. Practice-based pharmaceutical services: a systematic review. Int J Pharm Pract. 2002;10:225–233. doi: 10.1211/096176702776868451.
    1. Nkansah N, Mostovetsky O, Yu C, Chheng T, Beney J, Bond CM, Bero L. Effect of outpatient pharmacists’ non-dispensing roles on patient outcomes and prescribing patterns. Cochrane Database Syst Rev. 2010 doi: 10.1002/14651858.CD000336.pub2.
    1. Geurts MME, Talsma J, Brouwers JRBJ, De Gier JJ. Medication review and reconciliation with cooperation between pharmacist and general practitioner and the benefit for the patient: a systematic review. Br J Clin Pharmacol. 2012;74:16–33. doi: 10.1111/j.1365-2125.2012.04178.x.
    1. Tan ECK, Stewart K, Elliott RA, George J. Pharmacist services provided in general practice clinics: a systematic review and meta-analysis. Res Soc Adm Pharm. 2014;10:608–622. doi: 10.1016/j.sapharm.2013.08.006.
    1. Horne R. Compliance, adherence, and concordance: implications for asthma treatment. Chest. 2006;130(Suppl. 1):65S–72S. doi: 10.1378/chest.130.1_suppl.65S.
    1. Nunes V, Neilson J, O’Flynn N, Calvert N, Kuntze S, Smithson H, et al. Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. Clinical guidelines and evidence review for medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners 2009. . Accessed 1 Oct 2017.
    1. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: National Institute for Health and Clinical Excellence. 2013. . Accessed 25 May 2016.
    1. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4. Oxford: Oxford University Press; 2015.
    1. Baldi A, Kumar S. Pharmacoeconomics: principles, methods and economic evaluation of drug therapies. PhTechMed. 2013;2:362–369.
    1. AbuRuz SM, Bulatova NR, Yousef AM. Validation of a comprehensive classification tool for treatment related problems. Pharm Word Sci. 2006;28:222–232. doi: 10.1007/s11096-006-9048-0.
    1. Ruffieux C, Marazzi A, Paccaud F. Exploring models for the length of stay distribution. Soz Praventivmed. 1993;38:77–82. doi: 10.1007/BF01318464.
    1. Weissman C. Analyzing intensive care unit length of stay data: problems and possible solutions. Crit Care Med. 1997;25:1594–1600. doi: 10.1097/00003246-199709000-00031.
    1. Lee AH, Xiao J, Vemuri SR, Zhao Y. A discordancy test approach to identify outliers of length of hospital stay. Stat Med. 1998;17:2199–2206. doi: 10.1002/(SICI)1097-0258(19981015)17:19<2199::AID-SIM917>;2-2.
    1. Busby J, Purdy S, Hollingworth W. Calculating hospital length of stay using the Hospital Episode Statistics; a comparison of methodologies. BMC Health Serv Res. 2017;17:347. doi: 10.1186/s12913-017-2295-z.
    1. Gaughan J, Gravelle H, Santos R, Siciliani L. Long term care provision, hospital length of stay and discharge destination for hip fracture and stroke patients. 2013. Accessed 14 July 2019.
    1. Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials. Oxford: Oxford University Press. ISBN 978-0-19852997-2. 2007. pp 145–146.
    1. National Institute for Health and Clinical Excellence. Social Value Judgements: Principles for the Development of NICE Guidance. London: National Institute for Health and Clinical Excellence. 2008. . Accessed 25 May 2016.
    1. Shah K, Cookson RA, Culyer AJ, Littlejohns P. NICE’s social value judgements about equity in health and health care. Discussion Paper. CHE Research Paper. Centre for Health Economics, University of York, York, UK. 2011. social_value judgements_about_equity_in_health.pdf. Accessed 1 Feb 2019.
    1. Murad MH, Asi N, Alsawas M, Alahdab F. New evidence pyramid. Evid Based Med. 2016;21:125–127. doi: 10.1136/ebmed-2016-110401.
    1. Montori VM, Guyatt GH. Intention-to-treat principle. CMAJ. 2001;165:1339–1341.
    1. Sheikh A, Smeeth L, Ashcroft R. Randomised controlled trials in primary care: scope and application. Br J Gen Pract. 2002;52:746–751.
    1. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290:1624–1632. doi: 10.1001/jama.290.12.1624.
    1. Jódar-Sánchez F, Malet-Larrea A, Martín JJ, García-Mochón L, López Del Amo MP, Martínez-Martínez F, Gastelurrutia-Garralda MA, García-Cárdenas V, Sabater-Hernández D, Sáez-Benito L, Benrimoj SI. Cost-utility analysis of a medication review with follow-up service for older adults with polypharmacy in community pharmacies in Spain: the conSIGUE program. Pharmacoeconomics. 2015;33:599–610. doi: 10.1007/s40273-015-0270-2.
    1. Lau E, Dolovich L. Drug-related problems in elderly general practice patients receiving pharmaceutical care. Int J Pharm Pract. 2005;13:165–177. doi: 10.1211/ijpp.13.3.0002.
    1. Lenander C, Elfsson B, Danielsson B, Midlov P, Hasselstrom J. Effects of a pharmacist-led structured medication review in primary care on drug-related problems and hospital admission rates: a randomized controlled trial. Scand J Prim Health Care. 2014;32:180–186. doi: 10.3109/02813432.2014.972062.
    1. Avery T, Barber N, Ghaleb B, Franklin BD, Armstrong S, Crowe S, Dhillon S, Freyer A, Howard R, Pezzolesi C, Serumaga B, Swanwick G, Olanrenwaju T. Investigating the prevalence and causes of prescribing errors in general practice : The PRACtICe Study (PRevalence And Causes of prescrIbing errors in general practiCe) A report for the GMC. 2012. . Accessed 20 Sept 2016.
    1. Lowrie R, Lloyd SM, McConnachie A, Morrison J. A cluster randomised controlled trial of a pharmacist-led collaborative intervention to improve statin prescribing and attainment of cholesterol targets in primary care. PLoS ONE. 2014 doi: 10.1371/journal.pone.0113370.t001.
    1. Gillespie U, Alassaad A, Hammarlund-Udenaes M, Mörlin C, Henrohn D, Bertilsson M, Melhus H. Effects of pharmacists’ interventions on appropriateness of prescribing and evaluation of the instruments' (MAI, STOPP and STARTs') ability to predict hospitalization—analyses from a randomized controlled trial. PLoS ONE. 2013;8:e62401. doi: 10.1371/journal.pone.0062401.
    1. Wolf C, Pauly A, Mayr A, Grömer T, Lenz B, Kornhuber J, Friedland K. Pharmacist-led medication reviews to identify and collaboratively resolve drug related problems in psychiatry—a controlled. Clin Trial PLoS One. 2015 doi: 10.1371/journal.pone.0142011.
    1. Burnett KM, Scott MG, Fleming GF, Clark CM, McElnay JC. Effects of an integrated medicines management program on medication appropriateness in hospitalized patients. Am J Health-Syst Pharm. 2009;66:854–859. doi: 10.2146/ajhp080176.
    1. Patterson SM, Hughes C, Kerse N, Cardwell CR, Bradley MC. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2012;CD008165.
    1. Patterson SM, Cadogan CA, Kerse N, Cardwell CR, Bradley MC, Ryan C, Hughes C. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2014;CD008165.
    1. Hanlon JT, Weinberger M, Samsa GP, Schmader KE, Uttech KM, Lewis IK, et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med. 1996 doi: 10.1016/S0002-9343(97)89519-8.
    1. Schmader KE, Hanlon JT, Landsman PB, Samsa GP, Lewis IK, Weinberger M. Inappropriate prescribing and health outcomes in elderly veteran outpatients. Ann Pharmacother. 1997;31:529–533. doi: 10.1177/106002809703100501.
    1. Fick DM, Waller JL, Maclean JR. Potentially inappropriate medication use in a medicare managed care population: association with higher costs and utilization. J Manag Care Pharm. 2001;7:407–413.
    1. Gillespie U, Alassaad A, Hammarlund-Udenaes M, Mörlin C, Henrohn D, Bertilsson M, Melhus H. Effects of pharmacists’ interventions on appropriateness of prescribing and evaluation of the instruments' (MAI, STOPP and STARTs') ability to predict hospitalization—analyses from a randomized controlled trial. PLoS ONE. 2013 doi: 10.1371/journal.pone.0062401.
    1. Gillespie U, Alassaad A, Henrohn D, Garmo H, Hammarlund-Udenaes M, Toss H, Kettis-Lindblad A, Melhus H, Mörlin C. A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older: a randomized controlled trial. Arch Intern Med. 2009;169:894–900. doi: 10.1001/archinternmed.2009.71.
    1. Royal S, Smeaton L, Avery AJ, Hurwitz B, Sheikh A. Interventions in primary care to reduce medication related adverse events and hospital admissions: systematic review and meta-analysis. Qual Saf Health Care. 2006;15:23–31. doi: 10.1136/qshc.2004.012153.
    1. Khalil H, Bell B, Chambers H, Sheikh A, Avery AJ. Professional, structural and organisational interventions in primary care for reducing medication errors. Cochrane Database Syst Rev. 2017;CD003942.
    1. Obreli-Neto PR, Marusic S, Guidoni CM, Baldoni AO, Renovato RD, Pilger D, Cuman RKN, Pereira LRL. Economic evaluation of a pharmaceutical care program for elderly diabetic and hypertensive patients in primary health care: a 36-month randomized controlled clinical trial. J Manag Care Spec Pharm. 2015;21:66–75.
    1. Avery AJ, Rodgers S, Cantrill JA, Armstrong S, Cresswell K, Eden M, Elliott RA, Howard R, Kendrick D, Morris CJ, Prescott RJ, Swanwick G, Franklin M, Putman K, Boyd M, Sheikh A. A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis. Lancet. 2012;379:1310–1319. doi: 10.1016/S0140-6736(11)61817-5.
    1. Khdour MR, Agus AM, Kidney JC, Smyth BM, McElnay JC, Crealey GE. Cost-utility analysis of a pharmacy-led self-management programme for patients with COPD. Int J Clin Pharm. 2011;33:665–673. doi: 10.1007/s11096-011-9524-z.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe